Search results for "Disease duration"

showing 7 items of 7 documents

Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database

2019

ObjectivesA few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response.MethodsWe applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP.ResultsAt the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 …

AdultMaleTreatment responselewis-sumner syndromeAdolescentDatabases FactualDisease durationchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; Surgery; Neurology (clinical); Psychiatry and Mental HealthKaplan-Meier EstimateCIDPcomputer.software_genreDisease courseYoung Adultlewis–sumner syndrome03 medical and health sciences0302 clinical medicineHumansMedicineIn patientChildAgedRetrospective StudiesAged 80 and overchronic inflammatory demyelinating polyradiculoneuropathyRetrospective reviewdistal acquired demyelinating symmetric neuropathyDatabasebusiness.industryPolyradiculoneuropathyMiddle Agedchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndromemedicine.diseasePsychiatry and Mental healthchronic inflammatory demyelinating polyradiculoneuropathy; CIDP; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis-sumner syndrome; surgery; neurology ; psychiatry and mental healthItalyPolyradiculoneuropathy Chronic Inflammatory Demyelinatingdiagnostic criteriaDisease ProgressionFemaleSettore MED/26 - NeurologiaSurgeryProgression rateNeurology (clinical)CIDP; chronic inflammatory demyelinating polyradiculoneuropathy; diagnostic criteria; distal acquired demyelinating symmetric neuropathy; lewis–sumner syndromebusinesscomputer030217 neurology & neurosurgeryJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of …

2018

PurposeTo compare the functional and anatomical outcomes of eyes with chronic central serous chorioretinopathy treated with yellow micropulse (MP) laser versus half-dose verteporfin photodynamic therapy (PDT).MethodsThis is a multicentre, retrospective comparative study of 92 eyes treated with yellow MP laser (duty cycle of 5%, zero spacing between spots, spot size varied from 100 to 200 µm, power varied from 320 to 660 mW, and the pulse burst duration was 200 ms) and 67 eyes treated with PDT (half-dose verteporfin (3 mg/m2) infused over 10 min), followed by laser activation for 83 s. Spot sizes varied from 400 to 2000 µm.ResultsIn the MP group, at 12 months of follow-up, the mean best corr…

Laser surgeryMaleFluorescein angiographyretinaVisual acuityoptical coherencegenetic structuresPhysiologymedicine.medical_treatmentCentral serous chorioretinopathyVisual AcuityPhotodynamic therapytreatment lasersProceduresPhotodynamic therapychemistry.chemical_compound0302 clinical medicineBest corrected visual acuityMedicineFluorescein AngiographyTreatment outcomeMiddle agedTomographyPriority journalLow level laser therapyPhotosensitizing Agentsmedicine.diagnostic_testMiddle AgedFluorescein angiographyVerteporfinPhotosensitizing agentsSensory SystemsIndocyanine greenMulticenter studyBevacizumabClinical trialRetrospective studyTreatment OutcomeCentral Serous ChorioretinopathyFemaleLaser Therapymedicine.symptomTomography Optical Coherencemedicine.drugHumanIndocyanine GreenAdultmedicine.medical_specialtyVisual acuityLaser surgeryMajor clinical studyFollow-up studiesPathophysiologyArticleChronic disease03 medical and health sciencesCellular and Molecular NeuroscienceLaser therapyOphthalmologyFluorescence angiographyHumansmaculaLow level laser therapyRetrospective StudiesDisease durationPhotosensitizing agentOptical coherence tomographybusiness.industryIntermethod comparisonSubretinal neovascularizationCentral serous retinopathyVerteporfinFollow upmedicine.diseaseMulticenter study (topic)eye diseasesRetrospective studiesOphthalmologyCentral serous retinopathychemistryPhotochemotherapyChronic Disease030221 ophthalmology & optometryYellow micropulse laserComparative studysense organsbusinessIndocyanine greenControlled study030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Inflammatory bowel disease in patients over the age of 70y. Does the disease duration influence its behavior?

2018

Introduction: The fastest growing segment of our population is that of people above 70 years of age. Elderly patients with IBD exhibit several specific problems. Our objective was to evaluate the clinical course, the side effects of the treatments and the need for surgery of elderly patients, regardless of the age of onset.Materials and Methods: This was a cross-sectional study wherein retrospective data were collected from multiple centers from seven hospitals within the Valencia metropolitan area. Data were collected on patients older than 70y with inflammatory bowel disease.Results: We identified a total of 331 patients older than 70 years of age (5.3% of patients monitored at our center…

Malemedicine.medical_specialtyDisease durationPopulationComorbiditymacromolecular substancesInflammatory bowel diseaseGastroenterology03 medical and health sciencesElderly0302 clinical medicineAdrenal Cortex HormonesNeoplasmsInternal medicinemedicineHumansImmunologic FactorsIn patientMesalamineeducationAgedRetrospective Studiesulcerative colitisAged 80 and overCrohn's diseaseeducation.field_of_studybusiness.industrymusculoskeletal neural and ocular physiologyGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisCrohn's diseaseCross-Sectional StudiesLogistic ModelsSpainSurgical Procedures Operative030220 oncology & carcinogenesisDisease ProgressionFemale030211 gastroenterology & hepatologybusiness
researchProduct

P124 The impact of the new American college of cardiology/american heart association (ACC/AHA) definition of hypertension on atherosclerotic vascular…

2020

Background The 2017 ACC/AHA guidelines define hypertension as ≥130/80 mmHg instead of ≥140/90 mmHg. Studies in systemic autoimmune diseases, where blood pressure (BP) is fluctuating over time, were not considered. Our aim was to assess the impact of the new definition on the prevalence and incidence of atherosclerotic vascular events (AVEs) in systemic lupus erythematosus (SLE). Patients-Methods SLE patients with at least two years of follow-up and no previous AVEs were divided in three groups (≥140/90 mmHg, 130–139/80–89 mmHg and Results 1532 patients satisfied the inclusion criteria (88.1% females, mean age at baseline 36.2±14.3 years, mean disease duration 6.1±6.3 years). The prevalence …

medicine.medical_specialtyBlood pressurebusiness.industryInternal medicineDisease durationIncidence (epidemiology)CardiologyMedicineCumulative incidenceMean agebusinessCardiovascular outcomesPoster presentations
researchProduct

Mortality in multiple sclerosis: a review

2008

This work was undertaken to evaluate studies on mortality caused by multiple sclerosis (MS), to evaluate if useful inferences can be drawn from survival studies that can be applied to clinical practice. A literature search was carried out to find epidemiological studies on MS prognosis, survival, mortality and causes of death relevant to our aim. The World Health Organization (WHO) reports on worldwide cause-specific mortality were also considered. Studies were evaluated according to the duration of the follow-up study, the year of publication and the methodology used. We evaluated MS survival from a methodological point of view and considered if time trends could be drawn from study result…

medicine.medical_specialtyeducation.field_of_studyPediatricsbusiness.industryMultiple sclerosisDisease durationPopulationmedicine.diseaseWorld healthClinical PracticeNeurologyOlder patientsEpidemiologymedicineNeurology (clinical)businessIntensive care medicineeducationCause of deathEuropean Journal of Neurology
researchProduct

THU0248 GLOMERULAR AND TUBULOINTERSTITIAL LESIONS IN PER-PROTOCOL REPEAT BUT NOT BASELINE KIDNEY BIOPSY PORTEND RELAPSE AND LONG-TERM RENAL FUNCTION …

2020

Background:In patients with lupus nephritis (LN), clinical response to treatment and renal histopathology have been shown to be discordant. No clinical or laboratory markers have to date been shown to reliably portend renal prognosis, in particular renal function impairment.Objectives:To investigate whether per-protocol repeat renal biopsies are predictive of LN relapses and long-term impairment of renal function.Methods:Forty-two patients with an incident biopsy-proven active proliferative (class III/IV ± V) LN from the LN database of the Université catholique de Louvain were included in the present retrospective study. Per-protocol repeat kidney biopsies were performed in all patients aft…

medicine.medical_specialtyeducation.field_of_studymedicine.diagnostic_testbusiness.industryDisease durationImmunologyPopulationLupus nephritisRenal functionmedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyRheumatologyInternal medicineCohortBiopsymedicineImmunology and AllergyOrgan involvementStatistical analysiseducationbusinessAnnals of the Rheumatic Diseases
researchProduct

A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analy…

2018

Abstract Background Adalimumab and golimumab are effective in the treatment of moderate to severe ulcerative colitis. Aims We reported the comparative effectiveness of adalimumab and golimumab in ulcerative colitis. Methods 118 patients treated with adalimumab and 79 treated with golimumab were included and evaluated at 8 weeks and at the end of follow up. Results Overall clinical benefit was 72.6% at 8 weeks and 58.9% at the end of follow up. Patients with longer disease duration and those treated with adalimumab had a better outcome. Clinical benefit was 78.8% in adalimumab patients and 63.3% in golimumab patients (p = 0.026) after 8 weeks; it was 66.9% in adalimumab patients and 46.8% in…

musculoskeletal diseasesModerate to severeAdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaBiologicDisease durationAdalimumab; Biologics; Golimumab; Ulcerative colitis; Adalimumab; Adult; Antibodies Monoclonal; Colitis Ulcerative; Female; Humans; Italy; Logistic Models; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alphaUlcerativeBiologicsGolimumabSeverity of Illness IndexTreatment failureAntibodies03 medical and health sciences0302 clinical medicineInternal medicineMonoclonalAdalimumabmedicineHumansskin and connective tissue diseasesAdalimumab; Biologics; Golimumab; Ulcerative colitis; Hepatology; GastroenterologyPropensity ScoreProportional Hazards ModelsHepatologybusiness.industryTumor Necrosis Factor-alphaGastroenterologyAdalimumabAntibodies MonoclonalMiddle Agedmedicine.diseaseColitisUlcerative colitishumanitiesGolimumabLogistic ModelsTreatment OutcomeUlcerative colitisItaly030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyColitis UlcerativeFemalebusinessmedicine.drug
researchProduct